Hoping that positive results will be achieved, China has allowed for clinical trials of Gilead Science's remdesivir. 761 patients are to be involved in this clinical trial.
This decision was made following the promising preclinical results of chloroquine and remdesivir.
In-vitro results show that these two grugs actively inhibit the novel Corona Virus (2019-nCoV).
These compounds have been used in human patients before and have been reported to have a safety track record by a team of researchers and these two drugs were assessed along with five other drugs.
Though it is reported that remdesivir is sufficiently effective, investigations are still underway and therefore, more information will be coming through.
